End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.
about
Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineHuman papillomavirus vaccination in low-resource countries: lack of evidence to support vaccinating sexually active womenLong-term efficacy and safety of human papillomavirus vaccinationSafety of human papillomavirus vaccines: a reviewHuman papillomavirus virus (HPV) genotype- and age-specific analyses of external genital lesions among men in the HPV Infection in Men (HIM) StudyMultisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.Advanced MRI in malignant neoplasms of the uterus.Safety of human papillomavirus vaccines: a review.HPV vaccination in women aged 27 to 45 years: what do general practitioners think?HPV catch-up vaccination of young women: a systematic review and meta-analysis.Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policiesEffect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.Simultaneous detection and differentiation of human papillomavirus genotypes 6, 11, 16 and 18 by AllGlo quadruplex quantitative PCREquity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands.An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain.Vulval cancer and HPV vaccination in recurrent diseaseHuman papillomavirus prevalence and type distribution among women attending routine gynecological examinations in Saudi Arabia.Human papilloma virions in the laboratory.Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine.Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult womenHuman papillomavirus prevalence and type-distribution in women with cervical lesions: a cross-sectional study in Sri LankaSystematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure.Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.The role of sexual behavior in head and neck cancer: implications for prevention and therapy.Human papillomavirus knowledge, vaccine acceptance, and vaccine series completion among female entertainment and sex workers in Phnom Penh, Cambodia: the Young Women's Health Study.Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.Incidence of and risk factors for type-specific anal human papillomavirus infection among HIV-positive MSMMother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccineCompletion of the human papillomavirus vaccine series among insured females between 2006 and 2009A review of clinical trials of human papillomavirus prophylactic vaccines.Cross-sectional study about primary health care professionals views on the inclusion of the vaccine against human papillomavirus in the vaccine schedules.Prevalence of human papilloma virus (HPV) and its genotypes in cervical specimens of Egyptian women by linear array HPV genotyping testQuadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.Human papillomavirus vaccination in HIV-infected women: need for increased coverage.Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical diseaseRecommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected SubjectsType-specific human papillomavirus biological features: validated model-based estimatesIs human papillomavirus vaccination likely to be a useful strategy in India?
P2860
Q26749285-00EC758B-58E3-48C6-AF02-10D9D8D2419AQ26824062-82D3B393-056D-4AAC-970C-1403740AC7A4Q28081156-C83D57F6-400B-4681-ADDA-2837678EA086Q28082119-C3BF1D54-CC8B-4788-A341-EE4910B47D5DQ30303055-7AD0DFC7-7FE8-44E6-B592-48EFA18C4010Q30354637-DA591189-A5F1-476E-A267-3D7EF2E7B0A8Q30586370-1E656B90-BC4E-4A95-8D18-39C56B0EC7CEQ33162724-F156A2C0-615D-4D94-90B3-23A267F2751CQ34108157-ADE2543B-63DC-4A49-B526-22EDDE21F0B7Q34157209-DA64B905-024E-486E-99BB-ABE5A3080174Q34199773-7B6EF923-59D4-485A-A807-5AE9A706A3B5Q34210255-624E8A4A-585B-4C3A-AA1A-695928DB24BFQ34477633-2E09C48D-23D4-4DBD-B366-87D728FB2754Q34505091-F04E4A71-0B1C-4917-AF5B-262E688EEB3BQ34695768-50C67A95-3263-4194-8B2B-2D2FF037A211Q34733896-FAA41D30-EA35-4C87-BDCA-D77CB48D8AC7Q34746772-67761D10-5F8A-453A-BEDD-0AAB59CD255CQ34777995-8CD78468-9F7E-4000-9314-8C9739C562CCQ35005743-19163174-9634-4CAD-BBCA-B7B4E3F05D1BQ35082473-F931B300-9A52-4E89-ADC9-022B6C9F6412Q35099979-8E467C9E-53DE-4DC6-AAF3-4AE2B9D3D4ECQ35111092-33ECB6B5-CF29-4EC2-AF6E-0638B7AA4F65Q35127307-53E04C64-8472-40D4-88D2-8A1CE5FD3392Q35272050-7DB20A81-8F11-43FB-A3AA-D63CB45083A2Q35862810-1AE41225-94EE-4F75-A68B-1A89A36A44A1Q35901974-A7650C4D-55E0-4081-B819-D28133736077Q36001377-1F4B9EB5-0478-4E7B-9F87-F0C08F04D987Q36017795-B359BA8E-7B04-4319-B7B0-3D4F1AB891B6Q36133754-8F4E3B9F-B5AC-467C-A55E-D667AD6AAEC7Q36259403-3130941E-2520-4148-972F-7135BC7A6A44Q36281492-A54AE41D-0610-4E5E-9B45-37626730C89FQ36587825-44FC5076-173C-4548-A3BC-88A0981D241FQ36734952-E3408133-5565-4B2E-8F77-B8F4BD996D6CQ36780952-342EA269-6A55-439D-88DE-00F59C51ABEAQ36977831-460A1F16-942A-43DF-A1AA-E8E315BB8086Q37134986-8FBFFFB2-B9C8-46B1-871D-11EFE1870CF1Q37135485-4EF2B22E-AB2C-4742-9C36-23F1FF2C228AQ37221868-28CBEF3E-23CF-453C-AB41-09C7EDA23032Q37439328-DB562F74-1014-4485-BEB3-12FB1A8A497FQ37467149-513085E9-BFDE-476E-BA19-CE86E2425908
P2860
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
End-of-study safety, immunogen ...... dult women 24-45 years of age.
@ast
End-of-study safety, immunogen ...... dult women 24-45 years of age.
@en
type
label
End-of-study safety, immunogen ...... dult women 24-45 years of age.
@ast
End-of-study safety, immunogen ...... dult women 24-45 years of age.
@en
prefLabel
End-of-study safety, immunogen ...... dult women 24-45 years of age.
@ast
End-of-study safety, immunogen ...... dult women 24-45 years of age.
@en
P2093
P2860
P356
P1476
End-of-study safety, immunogen ...... dult women 24-45 years of age.
@en
P2093
J Monsonego
O M Bautista
P Pitisuttithum
P2860
P2888
P356
10.1038/BJC.2011.185
P407
P577
2011-05-31T00:00:00Z